000			03799nam a22003975i 4500
001			99966
003			DE-He213
005			20230110040159.0
007			cr nn 008mamaa
008			171109s2018 gw | s |||| 0|eng d
020			_a9783319602769 _9
024	7		_a10.1007/978-3-319-60276-9 _2doi
040			_aES-MaUEC _bspa
050		4	_aRC862.I53 _bT743 2018 EB
245	1	0	_aTreatment of Inflammatory Bowel Disease with Biologics _cedited by Adam S. Cheifetz, Joseph D. Feuerstein.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (XI, 335 páginas 22 ilustraciones, 19 ilustraciones a color)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
505	0		_aMechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn's Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn's Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics - Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies. .
520	3		_aThis book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
650		7	_aEnfermedad inflamatoria intestinal _2embne _9160162
650		7	_aGastroenterología _2embne _9141308
700	1		_aCheifetz, Adam S _eeditor literario _0http://id.loc.gov/authorities/names/n2010182768 _0http://viaf.org/viaf/129252794
700	1		_aFeuerstein, Joseph D _eeditor literario _0http://id.loc.gov/authorities/names/n2018183811 _0http://viaf.org/viaf/15152682575523312799
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319602752
776	0	8	_iEdición impresa: _z9783319602776
776	0	8	_iEdición impresa: _z9783319868233
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-60276-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aMedicine (Springer-11650)
988			_aSpringer_Medicine_2018
998			_b02/2019 _dz _ef _feng _ggw _h0
999			_c99966 _d99966 _x1